— Receives New Designation for Treatment of Platelet-Activating Anti-Platelet Factor 4 (PF4) Disorders  — Complements FDA Orphan Drug Designation and Fast Track Designation for VLX-1005 Frederick, MD, Aug. 14, 2024 … Read More

— New Financing of $24 Million Fully Funds the Phase 2 Clinical Program for Lead Candidate VLX- 1005 — Company Prepares to Evaluate VLX-1005 in Heparin-Induced Thrombocytopenia (HIT) FREDERICK, Md., … Read More

Development program for VLX-1005, a novel small molecule 12-LOX inhibitor, awarded Fast Track designation by US Food and Drug Administration FREDERICK, Md., June 13, 2022 — Veralox Therapeutics, a biotechnology … Read More

Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, today announced the appointment of Lisa Beck as … Read More

Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, today announced the appointment of Michael S. Hanna, … Read More

Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, today announced the closing of a $16.6 million … Read More